What We Offer

Working with the Kidney Cancer Research Consortium enables you to:

  • Collaborate with leading researchers across the country — big names with big ideas and a track record of research success.
  • Conduct cost-effective, multicenter trials at a fraction of the cost you would pay using a traditional CRO.
  • Access high volumes of RCC patients for trial enrollment, as well as serve underrepresented populations.
  • Propel innovative research, including biomarker development.
The Kidney Cancer Research Consortium (KCRC) offers multiple collaborative frameworks for pharmaceutical companies aiming to advance kidney cancer research and treatment. Whether through initiating new studies, sponsoring existing projects, or combining efforts, our models are designed to foster innovation and accelerate development in the fight against kidney cancer.

Investigator-Initiated Trials

These trials are led by KCRC researchers who propose and conduct studies based on their unique insights into kidney cancer. This model allows for scientific inquiry driven by frontline discoveries and clinical expertise, with potential for pharmaceutical support in aspects like drug provision or funding.

Hybrid Trials

Hybrid trials represent a collaborative approach, blending investigator-initiated ideas with the financial and logistical support of pharmaceutical sponsors. This model leverages the strengths of both entities to create highly flexible and effective research opportunities, targeting the most pressing challenges in kidney cancer.

Sponsored Trials

In this model, pharmaceutical companies directly sponsor clinical trials conducted within the KCRC. These partnerships are crucial for advancing research on new treatments and therapies, providing the essential resources and support to explore groundbreaking concepts in kidney cancer care.

Trial Execution & Design

We have a dedicated team focused on facilitating trial design and accelerating execution.

A major barrier to multicenter clinical trial execution has been the harmonization of regulatory processes required to open studies rapidly across participating centers.  Academic centers are now realizing that their continued relevance in the clinical trials world is dependent on being able to overcome these inefficiencies.

– efficient concept approval process
– accelerate clinical trial document generation
– streamline Consortium IRB review
– harmonize contracting across institutions
– risk based monitoring across institutions
– utilize performance metrics for clinical trial sites

Biomarker Discovery

A key goal of the Consortium is to enable the development of biomarkers that can predict response and anticipate resistance to novel therapies.  The Consortium will facilitate this by drawing on the expertise of the respective institutions in Pathology, Genomics, Imaging and Bioinformatics.

The Consortium emphasizes performing biopsies; collecting plasma, serum and urine; and proposing companion correlative studies in conjunction with the clinical trial itself.

Data Sets

Clinical trials and correlative studies generate huge amounts of data.  All aspects of clinical trial initiation, execution, and analysis are dependent on having a transparent, robust data-management system.

Consortium information technology personnel at MD Anderson have developed and delivered systems to support the capture of quality, structured research data. The Prometheus platform addresses gaps in institutional systems that support clinical and translational research.

Immunotherapy holds curative potential. It’s a real game changer in oncology, and we are helping to lead the way in the development of new treatments for kidney cancer patients.

– Dr. Hans Hammers

Kidney Cancer Research Consortium - Patient Information for Clinical Trials

Information for Patients

Patients with kidney cancer may benefit from participation in clinical trials at any point in their treatment. Read on for more information and to locate enrolling trials.

Kidney Cancer Research News - Kidney Cancer Research Consortium

Research News

Kidney cancer research is a rapidly-advancing area of oncology. Read about the latest research coming from Consortium sites and others researching treatment for RCC.

The Kidney Cancer Research Consortium Members

The Consortium members have over 100 years of combined experience in kidney cancer clinical research. KCRC brings an unmatched commitment to and expertise to RCC trials.